International Symposium on Reliable Distributed Systems

Clarion Safety Systems' Standards Expert is a Featured Instructor at the IEEE International Symposium on Product Compliance Engineering

Retrieved on: 
Thursday, April 20, 2023
Lambert, ISO, ANSI Z535, Electrical engineering technology, Electronics, ANSI, Institute of Electrical and Electronics Engineers, IEEE, International Symposium on Reliable Distributed Systems, Environment, Electricity, Safety, Automation

MILFORD, Pa., April 20, 2023 /PRNewswire-PRWeb/ -- The Institute of Electrical and Electronics Engineers' (IEEE) annual International Symposium on Product Compliance Engineering (ISPCE 2023) will feature a session from Angela Lambert, a safety and liability industry expert from Clarion Safety Systems. Clarion Safety is a leading designer and manufacturer of safety labels, signs, and tags – and provides complementary services for comprehensive machine safety, compliance, and risk reduction.

Key Points: 
  • Angela Lambert, head of standards compliance for Clarion Safety Systems, will be part of the Institute of Electrical and Electronics Engineers' annual Symposium on Product Compliance Engineering
    MILFORD, Pa., April 20, 2023 /PRNewswire-PRWeb/ -- The Institute of Electrical and Electronics Engineers' (IEEE) annual International Symposium on Product Compliance Engineering (ISPCE 2023) will feature a session from Angela Lambert, a safety and liability industry expert from Clarion Safety Systems.
  • Clarion Safety is a leading designer and manufacturer of safety labels , signs , and tags – and provides complementary services for comprehensive machine safety, compliance, and risk reduction .
  • ISPCE, which is the flagship conference of IEEE's Product Safety Engineering Society, will be held in Dallas, TX from May 1-3, 2023.
  • This year's program at ISPCE focuses on several key areas for safety and engineering professionals, including keynote presentations with various topics on:

Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

Retrieved on: 
Monday, October 17, 2022
SAN, Immunoglobulin G, AT-02, PAR, Disease, Therapy, Animal, Amyloid, MTD, ATTR, International Symposium on Reliable Distributed Systems, Patient, Tissue, Iodine, Mortality, SA, Technology, Degenerative disease, Mouse, Immune system, HV, End organ damage, Mab, Awareness, Safety, GLOBE, Clinical trial, AL, Forward-looking statement, PK, Index (publishing), Pharmaceutical industry, Medical imaging, Vaccine, Amyloidosis

The clinical trial is enrolling both healthy volunteers and patients with systemic amyloidosis.

Key Points: 
  • The clinical trial is enrolling both healthy volunteers and patients with systemic amyloidosis.
  • Based on the preclinical data, we believe AT-02 has the potential to remove existing amyloid and improve organ function and clinical outcomes for patients."
  • AT-02 is a full-length, humanized, recombinant immunoglobulin 1 (IgG1) monoclonal antibody (mAb) fusion protein that is being developed to treat systemic amyloidosis (SA).
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.

Ansys Wins Prestigious Best Paper Award at the IEEE HOST Conference for Pioneering Semiconductor Security Solution

Retrieved on: 
Tuesday, July 19, 2022
Paper, IEEE Computer Society, Electronics, ANSYS, Association, Time, Transport, POI, Semiconductor, Electricity, NASDAQ, Electrical engineering technology, Digital library, Silicon, ACM, Machine learning, Fred Brooks, Growth, International Symposium on Reliable Distributed Systems, Institute, IEEE, EDA, Printed circuit board, Instrumentation, Risk management, Consumer electronics, Ansys

PITTSBURGH, July 19, 2022 /PRNewswire/ -- Ansys (NASDAQ: ANSS) received the Best Paper Award from the Institute of Electrical and Electronics Engineers' (IEEE) International Symposium on Hardware Oriented Security and Trust (HOST), the world-leading hardware security conference. The winning paper introduces Ansys' latest semiconductor solution, Ansys RedHawk-SC Security, a new electronic design automation (EDA) tool to assess unintended data leakage vulnerabilities while providing fast and predictively accurate simulation integration. Unintended data leakage includes vulnerabilities stemming from power consumption, electromagnetic emission, thermal emission, and other multiphysics phenomena.

Key Points: 
  • The winning paper introduces Ansys' latest semiconductor solution, Ansys RedHawk-SC Security, a new electronic design automation (EDA) tool to assess unintended data leakage vulnerabilities while providing fast and predictively accurate simulation integration.
  • Ansys RedHawk-SC Security also features built-in security analytics to explain results to designers or engineers unfamiliar with hardware security.
  • "Selected from 120+ excellent submissions, Ansys' paper demonstrates the innovation and usability of the novel multiphysics simulation framework introducing Ansys RedHawk-SC Security."
  • "We are confident that Ansys RedHawk-SC Security will significantly enhance chip design and hardware security going forward."

MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)

Retrieved on: 
Thursday, October 21, 2021
Fibrosis, Form 8-K, Idiopathic pulmonary fibrosis, Kyoto International Conference Center, TG, Fatty liver disease, Gene, Annual report, Hypertriglyceridemia, Neurodegeneration, Failure, International Symposium on Reliable Distributed Systems, Triglyceride, NAFLD, Code, Security (finance), Substance dependence, MCP-1, U.S. Securities and Exchange Commission, NASDAQ, Arachidonic acid, FDA, Narration, Patient, Private Securities Litigation Reform Act, Multiple sclerosis, Â, MS, Risk, Tokyo Stock Exchange, Conference, CD36, Glioblastoma, National Institute of General Medical Sciences, Inflammation, Amyotrophic lateral sclerosis, CCR2, Form 10-K, IPF, Serum, DCM, NASH, Intellectual property, GLOBE, Associate, LOXL2, ALS, Nasdaq, PDE, Hepatocyte, Pharmaceutical industry

Dr. Oguras e-presentation with narration will be accessible on the ISA2021 website from October 25 to November 30, 2021.

Key Points: 
  • Dr. Oguras e-presentation with narration will be accessible on the ISA2021 website from October 25 to November 30, 2021.
  • Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, It has been observed that MN-001 treatment reduces serum TG levels in multiple previous clinical trials.
  • We are very pleased that Dr. Ogura will present new findings regarding the mechanism by which MN-001 alters intracellular triglyceride metabolism.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.

With its Eyes Set on Tech Innovation, SRDS Expands Leadership Team with New President and Global Chief Technology Officer

Retrieved on: 
Tuesday, November 17, 2020
International Symposium on Reliable Distributed Systems, Cision, Companies

NEW YORK, Nov. 17, 2020 /PRNewswire-PRWeb/ --Media platform SRDS (srds.com) has announced the appointment of two leading executives, with Heather Petaccio appointed President and Yigael Chetrit being named Global Chief Technology Officer.

Key Points: 
  • NEW YORK, Nov. 17, 2020 /PRNewswire-PRWeb/ --Media platform SRDS (srds.com) has announced the appointment of two leading executives, with Heather Petaccio appointed President and Yigael Chetrit being named Global Chief Technology Officer.
  • "As we identify our longer-term business goals and continue to transform SRDS into a cutting-edge digital player, I'm excited to welcome both Heather and Yigael to our team.
  • "I look forward to working with a strong diverse team led by Heather and guided by an experienced technologist as Yigael.
  • Under their leadership, SRDS will be adding valuable integrations of parent company Adwanted's proprietary technology ecosystem, as well as via strategic platform partnerships.